SecurityPTSI / P.A.M. Transportation Services, Inc. (693149106)
President & CEOCUSHMAN DANIEL H
IndustryTrucking, Except Local
Institutional Owners41
Institutional Shares1,871,268 - 30.28%
Common Shares Outstanding6,179,071 shares (as of 2018-03-31)
Institutional Value$ 64,427,000 USD

Institutional Stock Ownership and Shareholders()

PTSI / P.A.M. Transportation Services, Inc. Institutional Ownership

P.A.M. Transportation Services, Inc. (NASDAQ:PTSI) has 41 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,871,268 shares. Largest shareholders include Renaissance Technologies LLC, Dimensional Fund Advisors Lp, BlackRock Institutional Trust Company, N.A., Pacific Ridge Capital Partners, LLC, BlackRock Inc., Vanguard Group Inc, BlackRock Fund Advisors, Bridgeway Capital Management Inc, Lsv Asset Management, and Kernodle & Katon Asset Management Group, LLC.
P.A.M. Transportation Services, Inc. (NASDAQ:PTSI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ptsi"><img src="https://images.fintel.io/us-ptsi-so.png" alt="PTSI / P.A.M. Transportation Services, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 58,562 58,562 0.00 2,037 2,129 4.52
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 6,022 9,827 63.18 212 357 68.40
2018-05-11 13F-HR Pacific Ridge Capital Partners, LLC 169,631 156,804 -7.56 5,840 5,700 -2.40
2018-05-09 13F-HR NORTHERN TRUST CORP 15,825 15,198 -3.96 544 553 1.65
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 11,147 10,509 -5.72 383 381 -0.52
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 38,901 36,400 -6.43 1,339 1,323 -1.19
2018-05-15 13F-HR Invesco Ltd. 10,622 7,557 -28.86 366 275 -24.86
2018-05-15 13F-HR UBS Group AG 958 0 -100.00 33 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 18,932 19,386 2.40 652 705 8.13
2018-05-15 13F-HR VANGUARD GROUP INC 93,332 100,872 8.08 3,246 3,667 12.97
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 370,180 369,779 -0.11 12,875 13,441 4.40
2018-05-11 13F-HR MACQUARIE GROUP LTD 3,500 127
2018-05-09 13F-HR BlackRock Inc. 151,905 150,922 -0.65 5,230 5,486 4.89
2018-05-14 13F-HR EAM Investors, LLC 16,897 16,493 -2.39 588 600 2.04
2018-04-11 13F-HR Horrell Capital Management, Inc. 28,641 29,405 2.67 986 1,069 8.42
2017-05-12 13F-HR Kernodle & Katon Asset Management Group, LLC 44,004 44,004 0.00 1,143 717 -37.27
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 4,211 559 -86.73 145 20 -86.21
2018-05-14 13F-HR Renaissance Technologies LLC 362,100 380,528 5.09 12,467 13,832 10.95
2018-05-15 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 11,309 0 -100.00 389 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 11,787 10,757 -8.74 236 279 18.22
2018-05-15 13F-HR BARCLAYS PLC 2,600 805 -69.04 90 29 -67.78
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 0 1,085 0 39
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 171,212 170,807 -0.24 3,428 4,438 29.46
2018-05-04 13F-HR LSV ASSET MANAGEMENT 73,581 56,148 -23.69 2,559 2,040 -20.28
2018-05-11 13F-HR Delpha Capital Management, Llc 397 0 -100.00 14 0 -100.00
2018-05-08 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 11,558 11,577 0.16 402 421 4.73
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 88 62 -29.55 3 2 -33.33
2018-05-11 13F-HR Russell Investments Group, Ltd. 6,793 900 -86.75 242 33 -86.36
2017-02-10 13F-HR BlackRock Fund Advisors 65,797 77,813 18.26 1,317 2,022 53.53
2018-05-14 13F-HR MORGAN STANLEY 5,553 4,011 -27.77 191 146 -23.56
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 61 91 49.18 2 3 50.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 0 9,475 0 344
2018-05-08 13F-HR Alambic Investment Management, L.P. 6,855 0 -100.00 236 0 -100.00
2018-05-15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 1,506 0 -100.00 52 0 -100.00
2018-05-09 13F-HR FEDERATED INVESTORS INC /PA/ 0 44 0 2
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 18,125 18,125 0.00 630 658 4.44
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 15,908 38,890 144.47 548 1,414 158.03
2018-05-15 13F-HR DEUTSCHE BANK AG\ 5,899 14,545 146.57 203 527 159.61
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 13,164 479
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 568 568 0.00 20 21 5.00
2018-05-12 13F-HR Hillsdale Investment Management Inc. 15,119 15,119 0.00 521 550 5.57
2018-04-06 13F-HR Carroll Financial Associates, Inc. 250 250 0.00 8 9 12.50
2017-02-10 13F-HR BlackRock Advisors LLC 1,874 1,874 0.00 38 49 28.95
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 456 72 -84.21 16 3 -81.25
2018-05-10 13F-HR JP Morgan Chase & Co 3,808 5,781 51.81 132 210 59.09
2018-05-10 13F-HR Spark Investment Management LLC 7,600 9,000 18.42 261 327 25.29

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

Related News Stories

BRIEF-P.A.M. Transportation Services Commences Self Tender Offer To Purchase Up To 100,000 Shares

2018-05-08 reuters
* PAM TRANSPORTATION- COMMENCEMENT OF A MODIFIED “DUTCH AUCTION” TENDER OFFER TO BUY UP TO 100,000 SHARES AT NO LESS THAN $39 & NOT MORE THAN $43/SHARE (1-0)

CUSIP: 693149106